Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651587 | 1.00 | MEN1 (0.43) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL31521038 | 0.84 | MEN1 (0.44) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL2729216 | 0.81 | ACHE (0.53) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL15947704 | 0.80 | HTR5A (0.36) | KMT2ALMNAACHE | |
| SCHEMBL12017404 | 0.80 | HTR5A (0.36) | KMT2ALMNAACHE | |
| SCHEMBL15945437 | 0.80 | ACHE (0.35) | ACHE | |
| SCHEMBL659599 | 0.79 | HPGD (0.46) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL1703536 | 0.78 | ACHE (0.42) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL1662568 | 0.78 | ACHE (0.42) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL15894907 | 0.78 | ACHE (0.42) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MEN1 544/4885KMT2A 921/4885MAPT 470/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MEN1 1218/4885KMT2A 1345/4885MAPT 501/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MEN1 544/4885KMT2A 921/4885MAPT 470/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MEN1 636/4885KMT2A 929/4885MAPT 438/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MEN1 636/4885KMT2A 929/4885MAPT 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.